(NASDAQ: MREO) Mereo Biopharma Group's forecast annual revenue growth rate of 466.08% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 102.02%, and it is also forecast to beat the US market's average forecast revenue growth rate of 25.67%.
Mereo Biopharma Group's revenue in 2025 is $500,000.On average, 9 Wall Street analysts forecast MREO's revenue for 2025 to be $13,685,326,269, with the lowest MREO revenue forecast at $389,872,667, and the highest MREO revenue forecast at $29,908,803,165. On average, 9 Wall Street analysts forecast MREO's revenue for 2026 to be $31,629,016,851, with the lowest MREO revenue forecast at $0, and the highest MREO revenue forecast at $63,159,372,048.
In 2027, MREO is forecast to generate $77,973,737,733 in revenue, with the lowest revenue forecast at $6,549,860,805 and the highest revenue forecast at $115,290,917,230.